Microbiological aspects of the cryptococcosis in the post-HAART era;Aspectos microbiológicos de la criptococosis en la era post-TARGA

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 28, Issue SUPPL. 1, 2010, Pages 40-45

  Mazuelos, Estrella Martín ^a   García, Ana Isabel Aller ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

AIDS; Cryptococcosis; HAART

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOOD CULTURE; CEREBROSPINAL FLUID CULTURE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LYMPHADENITIS; MORBIDITY; PROGNOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CEREBROSPINAL FLUID; COLUMBIDAE; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DISEASE RESERVOIRS; DRUG RESISTANCE, FUNGAL; FUNGEMIA; HIV-1; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; MENINGITIS, CRYPTOCOCCAL;

EID: 76749116538     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(10)70007-0     Document Type: Article

References (44)

1. Martín-Mazuelos E., and Torres Rodríguez J.M. Criptococosis. In: Ausina Ruiz V., and Moreno Guillén S. (Eds). Tratado SEIMC de Enfermedades Infecciosas y Microbiología Clínica (2006), Panamericana, Madrid 625-629
2. Viviani M.A., and Tortorano A.M. Cryptocorcus. In: Anaisie E.J., McGinnis M.R., and Pfaller M.A. (Eds). Clinical mycology (2009), Churchill Livingstone, Nueva York 231-249
3. Graybill J.R., Sobel J., Saag M., van Der Horst C., Powderly W., Cloud G., et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis 30 (2000) 47-54
4. Crowe S.M., Carlin J.B., Stewart K.I., Lucas C.R., and Hoy J.F. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr (1991) 770-776
5. Mirza S.A., Phelan M., Rimland D., Graviss E., Hamill R., Brandt M.E., et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 36 (2003) 789-794
6. Manfredi R., Calza L., and Chiodo F. AIDS-associated Cryptococcus infection before and after the highly active antiretroviral therapy era: emerging management problems. Int J Antimicrob Agents 22 (2003) 449-452
7. Abruzzo G.K., Flattery A.M., Gill C.J., Kong L., Smith J.G., Krupa D., et al. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 39 (1995) 1077-1081
8. Ostrosky-Zeichner L., Alexander B.D., Kett D.H., Vazquez J., Pappas P.G., Saeki F., et al. Multicenter clinical evaluation of the (1-3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41 (2005) 654-659
9. Dixit A, Carroll SF, Qureshi ST. Cryptococcus gattii: an emerging cause of fungal disease in North America. Interdiscip Perspect Infect Dis. 2009 (En prensa).
10. Singh N., Lortholary O., Alexander B.D., Gupta K.L., John G.T., Pursell K., et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 40 (2005) 1756-1761
11. Perfect J.R., and Casadevall A. Cryptococcosis. Infect Dis Clin North Am 16 (2002) 837-874
12. Saha D.C., Xess I., Biswas A., Bhowmik D.M., and Padma M.V. Detection of Cryptococcus by conventional, serological and molecular methods. Med Microbiol 58 (2009) 1098-1105
13. Powderly W.G., Keath E.J., Sokol-Anderson M., Robinson K., Kirk D., Little J.R., et al. Amphotericin B-resistant Cryptococcus neoformans in a patient with AIDS. Infect Dis Clin Pract 1 (1992) 314-316
14. Armengou A., Pocar C., Mascaro J., and García-Bragado F. Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 23 (1996) 1337-1338
15. Aller A.I., Martin-Mazuelos E., Lozano F., Gomez-Mateos J., Steele-Moore L., Holloway W.J., et al. Correlation of fluconazole XMIs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 44 (2000) 1544-1548
16. Kantarcioglu A.S., and Yucel A. A flucytosine-resistant Cryptococcus neoformans (seroype D) strain isolated in Turkey from cutaneous lesions. Med Mycol 40 (2002) 519-523
17. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Document M27-A3. Wayne: Clinical and Laboratory Standards Institute; 2008.
18. Ghannoum M.A., Ibrahim A.S., Fu Y., Shafiq M.C., Edwards J.E., and Criddle R.S. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol 30 (1992) 2881-2886
19. Witt M.D., Lewis R.J., Larsen A., Milefchik E., Leal M.A., Haubrich R.H., et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis 22 (1996) 322-328
20. Jessup C.J., Pfaller M.A., Messer A., Zhang J., Tumberland M., Mbidde E.K., et al. Fluconazole susceptibility testing of C. neoformans: comparison of two microdilution methods and clinical correlates among isolates from Ugandan AIDS patients. J Clin Microbiol 36 (1998) 2874-2876
21. Colombo A.L., Barchiesi F., McGough D.A., and Rinaldi M.G. Comparisson of Etest with National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol 33 (1995) 535-540
22. Pfaller M.A., Messer S.A., Karlsson A., and Bolmstrom A. Evaluation of Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media. J Clin Microbiol 36 (1998) 2586-2589
23. Aller A.I., Martin-Mazuelos E., Gutierrez M.J., Bernal S., Chavez M., and Recio F.J. Comparison of Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents. J Antimicrob Chemother 46 (2000) 997-1000
24. Maxwell M.J., Messer S.A., Hollis R.J., Diekema D.J., and Pfaller M.A. Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans. J Clin Microbiol 41 (2003) 97-99
25. Lozano-Chiu M., Paetznick V.L., Ghannoum M.A., and Rex J.H. Detection of resistance to amphotericin B. among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using Etest and National Committee for Clinical Laboratory Standards M27-A Methodologies. J Antimicrob Chemother 36 (1998) 2817-2822
26. Dannaoui E., Abdul M., Arpin M., Michel-Neguyen A., Piens M.A., Favel A., et al. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother 50 (2006) 2464-2470
27. Clinical and Laboratory Standards Institute. 2004. Method for antifungal disk diffusion susceptibility testing of yeasts. Document M44-A. Wayne: Clinical and Laboratory Standards Institute; 2004.
28. Pfaller M.A., Messer S.A., Boyken L., Tendolkar S., Hollis R.J., and Diekema D.J. Evaluation of the NCCLS M44 P Disk Diffusion Method for determining suscepytibilities of 276 clinical isolates of Cryptococcus neoformans to fluconazole. J Clin Microbiol 42 (2004) 380-383
29. Pfaller M.A., Diekema D.J., Rinaldi M.G., Barnes R., Hu B., Velesov A.V., et al. Results of ASTEMIS DISK global antifungal surveillance study: a 6.5 year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole standardized dik diffusion testing. J Clin Microbiol 43 (2005) 5848-5859
30. Espinel-Ingroff A., Cantón E., Gibbs D., and Wang A. Correlation of NeoSensitabs tablet diffusion assay results on three different agar Media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole and voriconazole. J Clin Microbiol 45 (2007) 858-864
31. López-Jodra O., Torres-Rodriguez J.M., Mendez-Vazquez R., Ribas-Forcadell E., Modera-Lopez Y., Baro-Tomas T., et al. In vitro susceptibility of C. neoformans isolates to five antifungal drugs using a colorimetric system and the reference microbroth method. J Antimicrob Chemother 45 (2000) 645-649
32. Torres-Rodriguez J.M., and Alvarado-Ramirez E. In vitro susceptibilities to yeasts using ATB FUNGUS 2 method, compared with Sensititre Yeast One and standard CLSI (NCCLS) M27-A2 methods. J Antimicrob Chemother 60 (2007) 658-661
33. Brandt M.E., Pfaller M.A., Hajjrd R.A., Hamill J., Pappas P.G., Ringold A.L., et al. Trend in antifungal susceptibility of C. neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother 45 (2001) 3065-3069
34. Yildirian S.T., Fothergill A.W., Sutton D.A., and Rinaldi M.G. In vitro susceptibilities of cerebrospinal fluid isolates of C. neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592). Mycoses 45 (2002) 378-383
35. Pfaller M.A., Messer S.A., Boyken L., Hollis R.J., Rice C., Tendolkar S., et al. In vitro activities of voriconazole, posaconazole and fluconazole against 4169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 48 (2004) 201-205
36. Pfaller M.A., Messer S.A., Boyken L., Rice C., Tendolkar S., Hollis R.J., et al. Global trends in the antifungal susceptibility of C. neoformans (1990 to 2004). J Clin Microbiol 43 (2005) 2163-2167
37. Aller A.I., Claro R., Castro C., Serrano C., Colom M.F., and Martin-Mazuelos E. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain:1994-1996 and 1997-2005. Chemotherapy 53 (2007) 300-305
38. Perkins A., Gomez-Lopez A., Mellado E., Rodriguez-Tudela J.L., and Cuenca-Estrella M. Rates of antifungal resistance among clinical isolates of C. neoformans var. neoformans. J Antimicrob Chemother 56 (2005) 1144-1147
39. Datta K., Jain N., Sethi S., Rattan A., Cassadevall A., and Banerjee U. Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care. J Antimicrob Chemother 52 (2003) 683-686
40. Sar B., Monchy D., Vann M., Keo C., Sarthou J.L., and Buisson Y. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J Antimicrob Chemother 54 (2004) 563-565
41. Cappor M.R., Mandal P., Deb M., Aggarwal P., and Banerjee U. Current scenario of cryptococcosis and antifungal susceptibility pattern in India: a cause for reappraisal. Mycoses 51 (2008) 258-265
42. Thompson G.R., Wiederhold N.P., Fothergill A.W., Vallo A.V., Wickes B.L., and Patterson T.F. Antifungal susceptibilities among different serotypes of Cryptococcus gatii and Cryptococcus neoformans. Antimicrob Agents Chemother 53 (2009) 309-311
43. Trilles L., Fernandez-Torres B., Lazera Mdos S., Wanke B., and Guarro J. In vitro antifungal susceptibility of Cryptococcus gattii. J Clin Microbiol 42 (2004) 4815-4817
44. Gomez-Lopez A., Zaragoza O., Martins D.A., Melhem C., Rodriguez-Tudela J.L., and Cuenca Estrella M. In vitro susceptibility of Cryptococcus gattii clinical isolates. Clin Microbiol Infect 14 (2008) 727-739